Date of Award
Open Access Thesis
Medical Doctor (MD)
Peter W. Marks
Nikolai A. Podoltsev
Specific aims: This single-center, retrospective study compared overall survival and hospitalization in older patients with acute myeloid leukemia (AML) receiving first-line treatment with standard induction chemotherapy and decitabine therapy.
Methods: Between January 2000 and December 2009, 36 patients at Yale-New Haven Hospital age 65 years and older with newly diagnosed AML received standard induction chemotherapy (n=11), decitabine therapy (n=11), or supportive care only (n=14). Data obtained included baseline characteristics, achievement of remission, overall survival, inpatient and outpatient visits, and early death.
Results: When compared to standard induction chemotherapy, decitabine patients were significantly older (77 vs 69 years, P = .020) yet had a favorable but nonsignificant trend for increased overall survival (9 vs 7 months, P = .192) and spent significantly fewer days in the hospital (30 vs 41 days, P = .047). Supportive care patients were older (84.5 years) and had a median survival of only 0.6 months.
Conclusions: Compared to standard induction chemotherapy, decitabine as first-line therapy for AML in older patients reduced hospitalization and had a similar overall survival.
Clarke, William Thomas, "Less Intensive Therapy For Older Aml Patients" (2013). Yale Medicine Thesis Digital Library. 1783.